default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

294 shareholders file suit against Kolon TissueGene for damage compensation

Jeong Sae-im  Published 2019.06.14  10:51  Updated 2019.06.14 10:51

공유
default_news_ad2

Kolon TissueGene said in a public filing on Thursday that its 294 minority shareholders were pursuing 9.28 billion won ($7.83 million) compensation for their investment losses through a lawsuit at the Seoul Central District Court.

The defendants include the company, CEO Noh Moon-jong, two former CEOs Lee Woo-sok and Lee Bum-sup, former Kolon Group Chairman Lee Woong-yeol, Kolon TissueGene CFO Kweon Soon-wook, and Kolon TissueGene’s outside director, Lee Jang-ik.

The compensation sought by the shareholders is 6.76 percent of the company’s equity capital.

“We will actively respond to the lawsuit by appointing a legal representative,” Kolon TissueGene said.

same@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch